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DG2 and DG1 have different capacities to bind to live mouse motor nerve 











Mouse and human mAb ganglioside binding characteristics
mAb	 Isotype	 Immunogen	 Half-maximal	bindingA	 	 Affinity
	 	 	 GM1	 GA1	 GD1b	 GD1a	 KDB	 Ligand
Mouse
DG1 IgG2b HS19 LOSC (GM1+, GT1a+) 2.0 × 103 – – – 1.8 × 10–6 GM1
DG2 IgG3 GM1 liposome 2.5 × 103 6.7 × 102 2.0 × 102 – 3.5 × 10–7 GA1
MOG1 IgG3 GD1b liposome – – 5.0 × 103  1.0 × 10–8 GD1b
MOG35 IgG2b O:19 LOSC (GM1+, GD1a+) – – – 1.0 × 104 9.5 × 10–7 GD1a
HumanD
SM1 IgM Unknown 6.5 × 103 50 – – Unknown
DO1 IgM Unknown 5.5 × 103 4.3 × 103 5.7 × 103 – Unknown
AHalf-maximal binding values represent the reciprocal of the antibody concentration (in mg/ml) giving half maximal binding as determined by ELISA.  
BBiaCore analysis of antibody Fab fragments was used to determine the binding affinity (KD) of the antibodies to the shown ligands (29). CHS19 and 0:19 
are the C. jejuni strains from which the LOS species were isolated and used to immunize GalNAcT–/– mice (15). DCloned from human patients with acute 
and chronic motor neuropathy (38).
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Figure 1
Topical immunostaining of frozen diaphragm sections from WT, GD3s–/–, and GalNAcT–/– mice. Fluorescence was quantified as either the 
area of the NMJ (stained with αBTx-TRITC) that is covered by anti-GM1 ligand (i.e., FITC fluorescence) or as the intensity of the FITC signal 
overlying the NMJ. All ligands bound most abundantly at the GD3s–/– NMJ compared with the WT NMJ. *P < 0.05, WT versus GD3s–/–. All 
images were acquired at ×40 magnification. Scale bars: 60 μm. (A and B) CTB fluorescence is strong at the WT and GD3s–/– but absent 
at the GalNAcT–/– NMJs. (C) Examples of CTB binding at NMJs of each strain, taken under constant microscope settings to represent the 
quantifications shown in A and B. (D and E) Anti-GM1 mAb DG1 stains both the WT and GD3s–/– and is absent in the GalNAcT–/– NMJs. (F) 
DG1 topical staining. (G and H) DG2 binding profile is evident at WT and GD3s–/– but absent at the GalNAcT–/– NMJs. (I) DG2 binding at 
the WT, GD3s–/–, and GalNAcT–/– NMJs.
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The nerve terminal ligand for DG1 and DG2 and the immunopatho-






























Pathophysiological effects of anti-GM1 antibodies in living nerve-
muscle preparations ex vivo. (A) Reconstructed confocal images of 
triangularis sterni NMJs from GD3s–/– mice, following ex vivo incuba-
tion in CTB, DG2, and DG1. For CTB and DG2, axonal staining is pres-
ent along with staining of the parajunctional fibroblast. DG1 binding is 
undetectable. (B) Electrophysiology in ex vivo hemidiaphragm of WT 
and GD3s–/– mice. mAbs were applied, followed by a source of com-
plement, and under such conditions only DG2 caused an increase in 
MEPP frequency of each strain. Con, control. (C) DG1 effect in ex vivo 
hemidiaphragm (WT and GD3s–/–). Following ex vivo muscle nerve 
incubations in mAb (or Ringer’ s medium alone [R] as control), tissue 
was snap-frozen and sectioned for quantitative analysis. Graphs show 
IgG, C3c, and MAC deposition (quantified as the signal intensity over 
the NMJ). Neurofilament (NF) loss is quantified as area coverage over 
the NMJ. DG1 binding is undetectable in the WT NMJ and only weakly 
present in the GD3s–/– NMJ under maximal detection settings. MAC 
and C3c deposition do not translate into neurofilament loss. (D) The 
experiment was performed as described for C, but with the mAb DG2. 
DG2 is detectable in WT and GD3s–/– NMJs and activates comple-
ment to cause a neurofilament loss compared with Ringer’s medium 
alone–incubated control tissue. For both C and D, note that the y axes 
have been adjusted for clarity. *P < 0.05 compared with the Ringer’s 
control. Scale bars: 20 μm.
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Inhibitory interactions between GM1 and adjacent gangliosides form 
under solid-phase conditions. We speculated that the inability of 
DG1 to bind GM1 in the living plasma membrane was due to 

























Reactivity of anti-GM1 mAbs DG1 and DG2 to ganglioside complexes containing GM1 in solid phase. The ganglioside complex at each loca-
tion is established by combining the row and column labels. Thus, coordinates 1,4 and 4,1 represent GM1:GD1a complex. Wells labeled X are 
negative controls (methanol only). (A) ELISA. DG1 (left) and DG2 (right) both bind GM1 alone, with no difference in average OD. The binding 
of both antibodies to complexes of GM1 and GM2 or GD1a is reduced as compared with GM1 alone. No difference was observed with other 
combinations investigated (GM1:GM3, GM1:GD1b, and GM1:GD3). DG1 binding to complexes GM1:GM2 and GM1:GD1a was less than that 
of DG2. Mean results ± SEM from 3 experiments are shown. (B) PVDF glycoarrays. DG1 was the primary antibody on the left membrane, DG2 
on the right. Mean results ± SEM for 3 experiments are shown. No significant difference in GM1 binding was observed for the 2 antibodies. DG1 
binding to GM1 complexes was significantly reduced compared with GM1 alone (P < 0.05, significance level for these comparisons not indicated 
in graph). DG2 binding GM1 complexes was marginally different compared with GM1 alone but significant for GM1:GM2 and GM1:GD1a. The 
inhibitory effect of complexes on antibody binding is greater for DG1 than for DG2. The average absolute reduction in signal intensity for GM1:
GD1a complex, compared with GM1 alone, is 75.1% for DG1 and 18.2% for DG2 (P < 0.05). Error bars indicate SEM. 1, GM1; 2, GM2; 3, GM3; 
4, GD1a; 5, GD1b; 6, GD3. *P < 0.05, **P < 0.01.
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Access of DG1 to GM1 in the living membrane is prevented by a mask-


















































GM1 and GD1a colocalize to form an inhibitory environment for DG1 
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Human neuropathy-associated anti-GM1 mAbs also exert comple-
ment-mediated neuropathophysiological effects at the mouse motor nerve 















































































Effect of neuraminidase treatment on anti-GM1 antibody binding and 
pathogenic activity. (A) Reconstructed confocal images of DG1 bind-
ing at ex vivo GD3s–/– triangularis sterni NMJs. Left: DG1 binding in 
living tissue is undetectable at the NMJ (stained with αBTx-TRITC). 
Right: DG1 binding (FITC) following neuraminidase treatment of tis-
sue. DG1 binding overlies the NMJ and is colocalized with the axonal 
neurofilament staining (Cy5), suggesting that DG1 is binding to the 
presynaptic aspect (the axon terminal). (B) Ex vivo GD3s–/– hemidia-
phragm preparations, as described in Figure 2. Neuraminidase (N’ase) 
treatment of tissue prior to incubation with DG1 enabled DG1 to bind 
the NMJ (as shown by IgG deposition), fix complement, and cause a 
neurofilament loss. *P < 0.05 compared with control tissue incubated 
in Ringer’s (minus neuraminidase) followed by DG1. (C) Electrophysi-
ology. DG1 and NHS as a source of complement caused a massive 
increase in MEPP frequency in the ex vivo GD3s–/– NMJ only when 
applied to neuraminidase-pretreated tissue. Scale bars: 20 μm. Error 
bars represent SEM for experiments performed in triplicate.
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Figure 5
Localization of GM1 and GD1a to raft fractions in PC12 
cells. (A) PC12 cell immunostaining (original magni-
fication, ×40). DG1 binding to PC12 cells (shown in 
phase contrast) is not detectable despite the presence 
of GM1, as shown by CTB staining of cells. Scale 
bars: 15 μm. (B) Effect of neuraminidase on DG1 and 
MOG35 binding to PC12 cells. Double staining reveals 
that control cells are positively stained with MOG35 
(TRITC), with no binding of DG1 (FITC). Following 
neuraminidase treatment, MOG35 staining is dimin-
ished, with a concomitant increase in DG1 binding. 
Scale bars: 15 μm (images acquired at ×40 magnifica-
tion). (C) GM1 and GD1a pixel-by-pixel colocalization. 
FITC and TRITC (anti-GM1 and anti-GD1a, respec-
tively) images (×63 magnification) from double-stained 
PC12 cells, with colocalization appearing as yellow 
overlap. Plane-by-plane colocalization (linear scatter 
plot) shows strong colocalization. (D) Western blot of 
raft immunoprecipitation based on MOG35 binding, 
allowing isolation of GD1a-positive rafts by anti-mouse 
IgG–coated beads. In irrelevant antibody–incubated 
cells, no rafts were isolated by anti-mouse IgG–coat-
ed beads. Bound sample was concentrated (×10) to 
amplify any potentially weak signal. In MOG35-incu-
bated cells, a population of rafts was isolated by the 
beads. Isolated fractions contained the raft-associated 
protein flotillin, but not SNAP25, which was taken as 
evidence that the raft extraction procedure did not lead 
to coalescence of the heterogeneous raft population. 
Bound fractions also contained both the light chain 
(LC) and heavy chain (HC) of the anti-GD1a antibody, 
and the isolated rafts were positive for both GM1 and 
GD1a. SM, starting material; UB, unbound; B, bound; 
BC, bound concentrated.
research article


















Binding and neuropathophysiological effects of human anti-GM1 mAbs SM1 and DO1. (A) Ex vivo hemidiaphragm preparations from GD3s–/– 
mice, as described for Figure 2. SM1 only binds NMJs following neuraminidase treatment and then causes a complement-mediated neurofila-
ment loss. (B) The experiment was performed as described for A, but with DO1. (C) Absence of SM1 staining at GD3s–/– triangularis sterni NMJs 
(left), and presence of staining when the tissue was preincubated in neuraminidase (right). (D) Electrophysiological analysis of the effects of 
SM1 and DO1 at GD3s–/– hemidiaphragm NMJs, as described in Figure 4 for mouse mAb DG1. Following neuraminidase treatment, both SM1 
and DO1 bind at NMJs and cause a complement-dependent increase in MEPP frequency. Scale bars: 20 μm. Error bars represent SEM for 
experiments performed in triplicate.
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Immunostaining of live tissue. For triangularis sternae neuromuscular 
preparations, the rib cage was removed and pinned in a Sylgard-lined 
(Sigma-Aldrich) dish with standard Ringer’s medium (119 mM NaCl, 
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